Genelux (GNLX) vs Vicore Pharma AB (VCRE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Vicore Pharma AB is the larger company by market cap ($253.5 million vs $115.8 million), about 2.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GNLX | VCRE |
|---|---|---|
| Share price | $2.56 | $9.00 |
| Market cap | $115.83M | $253.48M |
| 1-day change | +2.40% | +2.04% |
| YTD return | -41.28% | — |
| 1-year return | -54.85% | — |
| EPS (TTM) | $-0.86 | $-2.10 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $8.54 | $17.80 |
| 52-week low | $2.29 | $7.88 |
| Distance from 52-week high | -70.01% | -49.44% |
| Analyst consensus | none | none |
| Avg. price target upside | +635.55% | +268.44% |
| Average volume | 274.69K | 16.33K |
| Shares outstanding | 45.25M | 28.16M |
| Employees | 25 | 46 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Vicore Pharma AB is about 2.2 times larger than Genelux by market value ($253.48M vs $115.83M).
About Genelux
GNLX stock →Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec (olvimulogene nanivacirepvec), a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 25 employees
About Vicore Pharma AB
VCRE stock →Vicore Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops therapies for the treatment of respiratory diseases in Sweden. The company develops Buloxibutid (C21), an orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) that is in Phase II clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF), as well as in Phase I clinical trial for treating pulmonary hypertension.
Health Care · Biotechnology: Pharmaceutical Preparations · 46 employees
GNLX vs VCRE FAQ
Which is bigger, Genelux or Vicore Pharma AB?
Vicore Pharma AB (VCRE) is larger, with a market capitalization of $253.48M compared with $115.83M for Genelux (GNLX).
Are Genelux and Vicore Pharma AB in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.